Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

12 Jun 2024

Abstract excerpt

Summary Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38865661
DOI: 10.1056/nejmoa2401530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell TherapyPMID 38865661Read ↗

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphomaSemantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal B cell lymphomaSemantic proximity Read ↗

Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features.Semantic proximity Read ↗

First-Ever CAR T-cell Therapy Approved in U.S.Semantic proximity Read ↗

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell TherapySemantic proximity Read ↗

Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?Semantic proximity Read ↗

Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patternsSemantic proximity Read ↗

CAR T-Cell Therapy in Large B-Cell LymphomaSemantic proximity Read ↗

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.